AxonicsAXNX
About: Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Employees: 797
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
22% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 72
0% more funds holding in top 10
Funds holding in top 10: 16 [Q1] → 16 (+0) [Q2]
0.02% less ownership
Funds ownership: 83.7% [Q1] → 83.68% (-0.02%) [Q2]
0% less funds holding
Funds holding: 227 [Q1] → 226 (-1) [Q2]
2% less capital invested
Capital invested by funds: $2.94B [Q1] → $2.87B (-$70.9M) [Q2]
3% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 37
39% less call options, than puts
Call options by funds: $7.44M | Put options by funds: $12.1M
Research analyst outlook
We haven’t received any recent analyst ratings for AXNX.
Financial journalist opinion
Based on 4 articles about AXNX published over the past 30 days